Taxoprexin Treatment for Advanced Skin Melanoma

NCT ID: NCT00249262

Last Updated: 2025-09-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2007-04-30

Brief Summary

To evaluate objective response rate and duration of response to weekly Taxoprexin®.

To evaluate the safety profile of weekly Taxoprexin® in this patient population.

To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with metastatic malignant melanoma being treated with weekly Taxoprexin® Injection.

Detailed Description

This is a Phase II open-label study of weekly Taxoprexin® Injection in patients with metastatic malignant melanoma who have not received cytotoxic agents for advanced disease. Patients may have been previously treated with immunological agents including Interleukin-2 and vaccines. Patients will receive Taxoprexin® Injection at a dose of 500mg/m2 intravenously by 1-hour infusion weekly for the first five weeks of a six week cycle. Treatment will continue until progression of disease, intolerable toxicity, refusal of continued treatment by patient or Investigator decision.

Conditions

Metastatic Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Taxoprexin

Taxoprexin 500 mg/m² intravenously every week for 5 weeks

Group Type: EXPERIMENTAL

Taxoprexin

Intervention Type: DRUG

Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.

Interventions

Taxoprexin

Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.

Intervention Type: DRUG

Other Intervention Names

Docosahexaenoic acid (DHA)-paclitaxel

Eligibility Criteria

Inclusion Criteria

1. Patients must have malignant skin/mucosal (non-choroidal) melanoma, and documented metastatic disease.

2. Patients must have at least one measurable lesion.

3. Patients must not have received prior systemic chemotherapy for metastatic disease. Prior treatment with immunotherapy or vaccine therapy is allowed.

4. At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other therapy.

5. At least 4 weeks (28 days) since prior radiotherapy to > 20% of the bone marrow and prior adjuvant chemotherapy.

6. Patients must have Eastern Cooperative Oncology Group performance status of 0-2.

7. Patients must be > 13 years of age. The safety of Taxoprexin has not been adequately studied in younger patients.

8. Patients must have adequate liver and renal function.

9. Patients must have adequate bone marrow function.

10. Life expectancy of at least 3 months

11. Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.

Exclusion Criteria

1. Patients who have received prior therapy with any taxane.

2. Patients whose primary site was the choroid (eye).

3. Patients who have a past or current history of neoplasm other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or other cancers treated for cure and with a disease-free survival longer than 5 years.

4. Patients with symptomatic brain metastasis (es).

5. Patients who are pregnant or nursing and patients who are not practicing an acceptable method of birth control. Patients may not breastfeed while on this study.

6. Patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).

7. Patients with current peripheral neuropathy of any etiology that is greater than grade one (1).

8. Patients with unstable or serious concurrent medical conditions are excluded.

9. Patients with a known hypersensitivity to Cremophor.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

American Regent, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark A Falone, MD

Role: STUDY_DIRECTOR

American Regent, Inc.

Other Identifiers

P01-04-21

Identifier Type: -

Identifier Source: org_study_id

NCT00411918

Identifier Type: -

Identifier Source: nct_alias